Literature DB >> 34116482

Reinvestigation of the structure-activity relationships of isoniazid.

Pooja Hegde1, Helena I M Boshoff2, Yudi Rusman3, Wassihun Wedajo Aragaw4, Christine E Salomon3, Thomas Dick4, Courtney C Aldrich5.   

Abstract

Isoniazid (INH) remains a cornerstone for treatment of drug susceptible tuberculosis (TB), yet the quantitative structure-activity relationships for INH are not well documented in the literature. In this paper, we have evaluated a systematic series of INH analogs against contemporary Mycobacterium tuberculosis strains from different lineages and a few non-tuberculous mycobacteria (NTM). Deletion of the pyridyl nitrogen atom, isomerization of the pyridine nitrogen to other positions, replacement of the pyridine ring with isosteric heterocycles, and modification of the hydrazide moiety of INH abolishes antitubercular activity. Similarly, substitution of the pyridine ring at the 3-position is not tolerated while substitution at the 2-position is permitted with 2-methyl-INH 9 displaying antimycobacterial activity comparable to INH. To assess the specific activity of this series of INH analogs against mycobacteria, we assayed them against a panel of gram-positive and gram-negative bacteria, as well as a few fungi. As expected INH and its analogs display a narrow spectrum of activity and are inactive against all non-mycobacterial strains evaluated, except for 4, which has modest inhibitory activity against Cryptococcus neoformans. Our findings provide an updated analysis of the structure-activity relationship of INH that we hope will serve as useful resource for the community.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Isoniazid; SAR

Mesh:

Substances:

Year:  2021        PMID: 34116482      PMCID: PMC8324568          DOI: 10.1016/j.tube.2021.102100

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   2.973


  38 in total

1.  Chemotherapy of experimental tuberculosis. VI. Derivatives of isoniazid.

Authors:  J BERNSTEIN; W P JAMBOR; W A LOTT; F PANSY; B A STEINBERG; H L YALE
Journal:  Am Rev Tuberc       Date:  1953-03

2.  The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes.

Authors:  Melvin P Weinstein; James S Lewis
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

3.  Antituberculous compounds. 23. Alkyl- and acylisonicotinic acid hydrazides.

Authors:  S Kakimoto; I Tone
Journal:  J Med Chem       Date:  1965-11       Impact factor: 7.446

4.  Bishydrazide derivatives of isoindoline as simple anion receptors.

Authors:  Paweł Dydio; Tomasz Zieliński; Janusz Jurczak
Journal:  J Org Chem       Date:  2009-02-20       Impact factor: 4.354

5.  Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.

Authors:  Thomas Schön; Pontus Juréen; Christian G Giske; Erja Chryssanthou; Erik Sturegård; Jim Werngren; Gunnar Kahlmeter; Sven E Hoffner; Kristian A Angeby
Journal:  J Antimicrob Chemother       Date:  2009-07-23       Impact factor: 5.790

Review 6.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

7.  The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.

Authors:  Richa Rawat; Adrian Whitty; Peter J Tonge
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

Review 8.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

9.  Antimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assay.

Authors:  Guilian Li; Lu-Lu Lian; Li Wan; Jingrui Zhang; Xiuqin Zhao; Yi Jiang; Li-Li Zhao; Haican Liu; Kanglin Wan
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

10.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

View more
  1 in total

1.  Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives.

Authors:  Violina T Angelova; Tania Pencheva; Nikolay Vassilev; Elena K-Yovkova; Rositsa Mihaylova; Boris Petrov; Violeta Valcheva
Journal:  Antibiotics (Basel)       Date:  2022-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.